Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$67.72 USD

67.72
3,579,078

-0.14 (-0.21%)

Updated May 17, 2024 04:00 PM ET

After-Market: $67.75 +0.03 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 249)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know

Gilead Sciences (GILD) closed at $73.94 in the latest trading session, marking a -0.4% move from the prior day.

Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $76.65, marking a +0.22% move from the previous day.

Gilead (GILD) Gets FDA Nod for Veklury for Hepatic Impairment

Gilead's (GILD) anti-viral treatment Veklury gets FDA approval for the treatment of COVID-19 in patients with mild, moderate or severe hepatic impairment.

The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics

Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics are part of the Zacks top Analyst Blog.

Biotech Stock Roundup: REGN Up on Approval, APLS, NVAX Gain on Updates & More

Regulatory updates from Regeneron (REGN) and Apellis (APLS) are in focus in the biotech sector.

Sheraz Mian headshot

Top Stock Reports for Merck, Philip Morris & QUALCOMM

Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), Philip Morris International Inc. (PM) and QUALCOMM Incorporated (QCOM).

Gilead's (GILD) Leukemia Study Progress Put on Clinical Hold

Gilead (GILD) faces a setback as the FDA puts a partial clinical hold on enrolling new patients in studies evaluating magrolimab for treating AML in the United States.

Biotech Stock Roundup: GLTO Plunges on Setback, BLUE Offers Updates & More

Regulatory updates from Galecto (GLTO) and Sonnet BioTherapeutics Holdings (SONN) are in focus in the biotech sector.

Gilead (GILD), Tentarix To Develop Cancer, Inflammation Therapies

Gilead (GILD) enters into a deal with Tentarix Biotherapeutics to discover and develop novel therapies for cancer and inflammation.

Should You Invest in the VanEck Biotech ETF (BBH)?

Sector ETF report for BBH

Gilead's (GILD) Q2 Earnings Miss, Revenues Beat on Oncology

Gilead's (GILD) Q2 earnings miss on litigation charges while revenues beat on strong oncology and HIV franchise.

Gilead (GILD) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Gilead Sciences (GILD) Q2 Earnings Lag Estimates

Gilead (GILD) delivered earnings and revenue surprises of -16.25% and 2.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Gilead (GILD) Gears Up to Report Q2 Earnings: What's in Store?

Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its second-quarter 2023 results.

Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $77.19, marking a -0.05% move from the previous day.

Biotech Stock Roundup: BIIB, GSK's Q2 Earnings, KOD Faces Setback & More

Earnings updates from Biogen (BIIB) and GSK (GSK) are in focus in the biotech sector.

Should SPDR Russell 1000 Yield Focus ETF (ONEY) Be on Your Investing Radar?

Style Box ETF report for ONEY

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $77.23, marking a -0.55% move from the previous day.

Gilead (GILD) Ends Myelodysplastic Syndromes Study on Magrolimab

Gilead Sciences, Inc. (GILD) discontinues phase III ENHANCE study, evaluating the potential of magrolimab as a treatment for higher-risk myelodysplastic syndromes, due to futility based on a planned analysis.

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

Smart Beta ETF report for IBB

Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know

Gilead Sciences (GILD) closed the most recent trading day at $78.96, moving +0.95% from the previous trading session.

Should You Invest in the iShares Biotechnology ETF (IBB)?

Sector ETF report for IBB

Is SPDR Russell 1000 Yield Focus ETF (ONEY) a Strong ETF Right Now?

Smart Beta ETF report for ONEY

Gilead's (GILD) Veklury Gets FDA Nod for Label Expansion

Gilead's (GILD) antiviral treatment Veklury (remdesivir) has now been approved for the treatment of COVID-19 patients with severe renal impairment, including those on dialysis.

Should IQ Chaikin U.S. Large Cap ETF (CLRG) Be on Your Investing Radar?

Style Box ETF report for CLRG